A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
=== Nile red === Nile red (also known as Nile blue oxazone) is formed by boiling Nile blue with sulfuric acid. This produces a mix of Nile red and Nile blue. Nile red is a lipophilic stain; it will accumulate in lipid globules inside cells, staining them red. Nile red can be used with living cells. It fluoresces strongly when partitioned into lipids, but practically not at all in aqueous solution.
==== Fatal infantile-onset phenotype ==== There is an ultra-rare, fatal infantile-onset phenotype that results in profound muscle weakness ("floppy baby") and respiratory failure within weeks of birth (perinatal asphyxia). Post-mortem biopsy showed a deficiency of myophosphorylase and abnormal glycogen accumulation in skeletal muscle tissue. This phenotype may also include premature birth and joint contractures. Two reported cases, in 1978 and 1989.
=== Heavy metal emissions in the air === In some circumstances, mainly depending on the origin and the composition of the raw materials used, the high-temperature calcination process of limestone and clay minerals can release in the atmosphere gases and dust rich in volatile heavy metals, e.g. thallium, cadmium and mercury are the most toxic. Heavy metals (Tl, Cd, Hg, ...) and also selenium are often found as trace elements in common metal sulfides (pyrite (FeS2), zinc blende (ZnS), galena (PbS), ...) present as secondary minerals in most of the raw materials. Environmental regulations exist in many countries to limit these emissions. As of 2011 in the United States, cement kilns are "legally allowed to pump more toxins into the air than are hazardous-waste incinerators."
Lymphatic tissues begin to develop by the end of the fifth week of embryonic development. Lymphatic vessels develop from lymph sacs that arise from developing veins, which are derived from mesoderm. The first lymph sacs to appear are the paired jugular lymph sacs at the junction of the internal jugular and subclavian veins. From the jugular lymph sacs, lymphatic capillary plexuses spread to the thorax, upper limbs, neck, and head. Some of the plexuses enlarge and form lymphatic vessels in their respective regions. Each jugular lymph sac retains at least one connection with its jugular vein, the left one developing into the superior portion of the thoracic duct. The spleen develops from mesenchymal cells between layers of the dorsal mesentery of the stomach. The thymus arises as an outgrowth of the third pharyngeal pouch.
Sources: en.wikipedia.org
The Battle of Binh Ba, also known as Operation Hammer, was a hard-fought, but one-sided, battle. Troops from the 5th Battalion, Royal Australian Regiment (5RAR) fought a PAVN/VC force in the village of Binh Ba, 5 kilometres (3.1 mi) north of Nui Dat in Phuoc Tuy Province resulting in 107 PAVN/VC killed and eight captured for the loss of one Australian killed.
== Publication == Acharya B, Acharya A, Gautam S, Ghimire SP, Mishra G, Parajuli N; et al. (2020). "Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis". Mol Biol Rep. 47 (5): 4065–4075. doi:10.1007/s11033-020-05413-7. PMID 32248381.{{cite journal}}: CS1 maint: multiple names: authors list (link) Acharya B, Meka RR, Venkatesha SH, Lees JR, Teesalu T, Moudgil KD (2020). "A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis". Mol Cell Probes. 51 101530. doi:10.1016/j.mcp.2020.101530. PMC 7245014. PMID 32035108.{{cite journal}}: CS1 maint: multiple names: authors list (link) Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD (2015). "IL-27-induced modulation of autoimmunity and its therapeutic potential". Autoimmun Rev. 14 (12): 1131–1141. doi:10.1016/j.autrev.2015.08.001. PMC 4628569. PMID 26253381.{{cite journal}}: CS1 maint: multiple names: authors list (link) Venkatesha SH, Dudics S, Acharya B, Moudgil KD (2014). "Cytokine-modulating strategies and newer cytokine targets for arthritis therapy". Int J Mol Sci. 16 (1): 887–906. doi:10.3390/ijms16010887. PMC 4307281. PMID 25561237.{{cite journal}}: CS1 maint: multiple names: authors list (link) Meka RR, Venkatesha SH, Acharya B, Moudgil KD (2019). "Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy". Nanomedicine (Lond). 14 (11): 1455–1469. doi:10.2217/nnm-2018-0501. PMC 6613046.
=== Other uses === CPA is useful in the treatment of hot flashes, for instance due to androgen deprivation therapy for prostate cancer. CPA is useful for suppressing the testosterone flare at the initiation of GnRH agonist therapy. It has been used successfully both alone and in combination with estrogens such as diethylstilbestrol for this purpose.
=== Legal status === In February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hyftor, intended for the treatment of angiofibroma. The applicant for this medicinal product is Plusultra pharma GmbH. Hyftor was authorized for medical use in the European Union in May 2023. Sirolimus, as Rapamune solution, was approved for medical use in the United States in 1999; and as Rapamune tablets in August 2000. Sirolimus, as Fyarro, was approved for medical use in the United States in November 2021. Sirolimus, as Hyftor, was approved for medical use in the United States in March 2022.
Arsenic (III) binding sites usually use thiol groups of cysteine residues. The catalysis involves thiolates of Cys72, Cys174, and Cys224. In an SN2 reaction, the positive charge on the SAM sulfur atom pulls the bonding electron from the carbon of the methyl group, which interacts with the arsenic lone pair to form an As−C bond, leaving SAH.
Sources: en.wikipedia.org
Encouraged by South Africa's apparent failure to detect the initial incursion, larger insurgent groups made their own infiltration attempts in February and March 1966. The second unit, "Group 2", was led by Leonard Philemon Shuuya, also known by the nom de guerre "Castro" or "Leonard Nangolo". Group 2 apparently become lost in Angola before it was able to cross the border, and the guerrillas dispersed after an incident in which they killed two shopkeepers and a vagrant. Three were arrested by the Portuguese colonial authorities in Angola, who were working off tips received from local civilians. Another eight, including Shuuya, had been captured between March and May by the South African police, apparently in Kavangoland. Shuuya later resurfaced at Kongwa, claiming to have escaped his captors after his arrest. He helped plan two further incursions: a third SWALA group entered Ovamboland that July, while a fourth was scheduled to follow in September.
Some vaccines contain live, attenuated microorganisms. Many of these are active viruses that have been cultivated under conditions that disable their virulent properties, or that use closely related but less dangerous organisms to produce a broad immune response. Although most attenuated vaccines are viral, some are bacterial in nature. Examples include the viral diseases yellow fever, measles, mumps, and rubella, and the bacterial disease typhoid. The live Mycobacterium tuberculosis vaccine developed by Calmette and Guérin is not made of a contagious strain but contains a virulently modified strain called "BCG" used to elicit an immune response to the vaccine. The live attenuated vaccine containing strain Yersinia pestis EV is used for plague immunization. Attenuated vaccines have some advantages and disadvantages. Attenuated, or live, weakened, vaccines typically provoke more durable immunological responses. Attenuated vaccines also elicit a cellular and humoral response. However, they may not be safe for use in immunocompromised individuals, and on rare occasions mutate to a virulent form and cause disease.
==== Complex and Function of Membrane Protein in Cholesterol Homeostasis ==== As mentioned before, scientists Monika Suchanek, Anna Radzikowski, and Christoph Thiele wanted to study protein-protein interaction in their natural environment. Specifically, the membrane proteins (in a complex and are SCAP, Insig-1, and SREBP) that regulate cholesterol homeostasis so they wanted to know what their function was and the complex structure. What they had found was that using this photo-reactive amino acid was incorporated efficiently into the protein by mammalian cells, but did not need to use modified tRNAs (transfer RNA's) or AARS's (aminoacyl tRNA syntheses) which that allowed the specific cross-linking needed. This cross-linking could be determined by western blotting and they had discovered a direct interaction between Insig-1 and PGRMC1 (a progesterone-binding membrane protein). All four of the membrane proteins are found in the endoplasmic reticulum and the complex responds to low cholesterol levels. Cells (COS7) that had HA (hemagglutinin tagged PGRMC1) and Myc tagged Insig-1 were grown with and without photo-Met. In the presence of photo-Met, Insig-1 and SCAP had cross-linked with PGRMC1; specifically, Insig-1 cross-linked had a strong band. The cross-linking was detected by immunoprecipitating detergent-extracts with an antibody to HA then the precipitant was tested for Insig-1 using western blotting with the antibody for Myc.
=== Production === Valve developed several VR prototypes, with three projects under development by 2017. They found the portal systems of their puzzle series Portal were disorienting in VR, but that the Half-Life systems were a natural fit. Walker said that Half-Life 3 had been a "terrifyingly daunting prospect", and the team saw VR as a way to return to the series. Additionally, they anticipated that fans would react negatively if Half-Life 3 were a VR-only game and felt a prequel carried less weight. Valve built prototypes using Half-Life 2 assets and narrowed the gameplay systems to those that best fit VR. VR affected almost every aspect of the design, including combat, level design and pacing. For example, shooting in VR, which requires the player to physically position their hand in space, is a different experience from aiming with traditional mouse-and-keyboard controls. Mike Morasky, the composer for Portal 2 and Team Fortress 2, wrote the score in consultation with Kelly Bailey, the composer for previous Half-Life games. He cited industrial music by acts such as Nine Inch Nails, the Prodigy and Skinny Puppy as inspiration. Half-Life: Alyx entered development around February 2016 and entered full production later that year. The team, comprising around 80 people, was the largest in Valve's history, and included Campo Santo, a studio Valve acquired in 2018. As Valve had repeatedly failed to see projects through, some staff were reluctant to join and many were skeptical that VR was the right direction.
=== Naturally occurring isotope variation === Natural processes result in broad variations in the D/H ratio (DHR) in different pools of hydrogen. KIEs and physical changes such as precipitation and evaporation lead to these observed variations. Seawater varies slightly, between 0 and −10 per mil, while atmospheric water can vary between about −200‰ to +100‰. Biomolecules synthesized by organisms, retain some of the D/H signature of the water which they were grown on, plus a large fractionation factor which can be as great as several hundred ‰. Large D/H differences, of thousands of ‰, can be found between Earth and other planetary bodies such as Mars, likely due to variations in isotope fractionation during planet formation and the loss of hydrogen into space.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.